Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the effects of three types of perioperative analgesia on the number of circulating cancer cells (representing minimal residual disease) following radical colon cancer surgery. Patients will be randomized into one of three groups. The intervention group will receive combined regional and general anesthesia during surgery and postoperative epidural analgesia. The two control groups will receive balanced general anesthesia and either morphine-based or piritramide-based postoperative analgesia. We hypothesize that epidural analgesia will be favorable to both piritramide-based and morphine-based analgesia and that piritramide-based analgesia will be favorable to morphine-based analgesia with regard to the number of circulating cancer cells and its development in the early postoperative period.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
• Collaborators: Brno University Hospital; Tomas Bata Hospital, Czech Republic
• Treatments: Morphine; Pirinitramide

Criteria

Inclusion Criteria:

• Patients undergoing open radical surgery for colon cancer (without known extension beyond colon)

• Age over 18 years

• Written informed consent

Exclusion Criteria:

• Allergy or intolerance of morphine, piritramide, marcaine, sufentanil or volatile anesthetics

• History of colon cancer resection

• Other cancer present (apart from those in complete long-term remission for minimum 6 months)

• Chronic opioid medication and/or opioid administration 7 days or less prior to surgery

• Any contraindication to thoracic epidural anesthesia/analgesia

• Systemic therapy with immunosuppressive drugs or corticoids (apart from topical and inhalational)

• Any surgery within the last 30 days (apart from minor day-case procedures)  - Chronic or acute infectious disease, particularly hepatitis, AIDS, tuberculosis